ThromBoDx has developed a bloodtest which detects early stage cancer. According to ‘Het Financieele Dagblad’ (FD) Illumina is paying € 70 mln. for ThromboDx. Illumina will place ThromBoDX in its recently established daughter company ‘Grail’; a company in which Bill Gates (Microsoft) and Jeff Bezos (Amazon) are participating.
Download the FD article ‘ Weer miljoenendeal in Nederlandse biotech‘
Downlaod the FD article ‘Verkocht aan een van ’swerelds ‘slimste’bedrijven’
About ThromboDx: a molecular diagnostics company that develops and commercializes blood-based diagnostics through its proprietary platelet-powered technology platform and has its offices in Amsterdam, The Netherlands. The technology platform addresses the need for an easily accessible, minimally invasive source for high quality disease-specific nucleic acids in several markets. thromboDx BV targets three major markets: Cancer Diagnostics, Infectious Disease Monitoring and Prenatal Testing. ThromboDx BV is embedded in the scientific and clinical infrastructure at the Cancer Center Amsterdam that allows rapid access to patient cohorts and clinical studies.
ThromBoDx received a Pre Seed Grant in 2012 and founder ThromBoDx Tom Wurdinger also was involved in Exbiome who participated in the Venture challenge Fall 2015.